secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001171843-23-003807
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus to present AB-729 and AB-836 data at EASL Congress 2023
---------------------------------------------------------------

- AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.
- 88% of subjects achieved HBsAg <100 IU/mL; 2 subjects reached HBsAg <LLOQ during IFN treatment.
- AB-836 capsid inhibitor: no viral breakthrough or enrichment of resistant variants after 28 days across 48 subjects.
- Multiple core protein variants observed at higher frequencies, suggesting viral plasticity at those sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/0001171843-23-003807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/f8k_060523.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-003807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer